Biopool Gets FDA Consent on Blood Clot Test Kit

Biopool International of Ventura has received U. S. Food and Drug Administration approval to market a test system designed to assess a patient’s risk for developing blood clots.

Biopool’s Spectrolyse Antithrombin-III Assay Kit is the company’s seventh product to receive FDA approval this year. The kit expands Biopool’s line of products dedicated to assessing the risks of clotting and bleeding disorders.

Specifically, the new kit measures the level of Antithrombin-III (AT-III) activity in human plasma. AT-III is vital to the formation of blood clots, and its deficiency is associated with an increased risk of thrombosis, Biopool officials said.

“We believe that the greater specificity and ease of use of our new test kit will result in more widespread testing for this protein deficiency, which will result in improved diagnosis and treatment,” said Michael D. Bick, Biopool’s chief executive officer.

Biopool products are sold to hospitals and laboratories worldwide.